AR028952A1 - Antagonistas receptores de trombina - Google Patents
Antagonistas receptores de trombinaInfo
- Publication number
- AR028952A1 AR028952A1 ARP010102821A ARP010102821A AR028952A1 AR 028952 A1 AR028952 A1 AR 028952A1 AR P010102821 A ARP010102821 A AR P010102821A AR P010102821 A ARP010102821 A AR P010102821A AR 028952 A1 AR028952 A1 AR 028952A1
- Authority
- AR
- Argentina
- Prior art keywords
- absent
- formula
- dotted line
- optionally substituted
- line represents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos heterocíclico substituidos que tienen la formula (1) o una sal farmacéuticamente aceptable de los mismos que han sido descriptos, en los cuales: Z es -(CH2)n-; formula (2); formula (3), en la cual R10 está ausente, o formula (4) en la cual R3 está ausente; la línea de puntos unica representa un doble enlace opcional; la doble línea de puntos representa un enlace unico opcional; n es 0-2; Het es un grupo heteroaromático mono-, bi- o tricíclico opcionalmente sustituido; B es û(CH2)n3-, donde n3 es 0-5, CH2-O-, -CH2S-, CH2-NR6-, -C(O)NR6-, -NR6C(O)-, ciclopropileno, alquenilo opcionalmente sustituido o alquinilo opcionalmente sustituido; X es -O- o -NR6- cuando la doble línea de puntos representa un enlace unico, o X es H, -OH o ûNHR20 cuando está ausente el enlace; Y es =O, =S, (H,H), (H,OH), o (H, alcoxi C1-6) cuando la doble línea de puntos representa un enlace unico, o cuando el enlace está ausente, Y es =O, =NOR17, (H,H), (H,OH), (H,SH), (H, alcoxi C1-6) o (H, amino-sustituido); R22 y R23 son independientemente ûOH, -OC(O)R30, OC(O)NR30R31, o alquilo opcionalmente sustituido, alquenilo, alquinilo, heterocicloalquilo, arilo, cicloalquilo, cicloalquenilo, carbonilo, amino, alcoxi, alqueniloxi, alquiniloxi, heterocicloalquiloxi, cicloalquiloxi o cicloalqueniloxi; o R22 y R10, o R23 y R11, pueden formar un anillo carbocíclico o heterocíclico, y las variables remanentes son tal como se han descripto en la memoria. También se han descripto composiciones farmacéuticas que contienen dichos compuestos y su uso como antagonistas receptores de trombina y aglutinantes para los receptores cannabinoides.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21172400P | 2000-06-15 | 2000-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR028952A1 true AR028952A1 (es) | 2003-05-28 |
Family
ID=22788091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010102821A AR028952A1 (es) | 2000-06-15 | 2001-06-13 | Antagonistas receptores de trombina |
Country Status (31)
Country | Link |
---|---|
US (2) | US6645987B2 (es) |
EP (2) | EP1294714B1 (es) |
JP (2) | JP4642318B2 (es) |
KR (1) | KR100604742B1 (es) |
CN (1) | CN1203070C (es) |
AR (1) | AR028952A1 (es) |
AT (1) | ATE368659T1 (es) |
AU (2) | AU6690001A (es) |
BR (1) | BR0111991A (es) |
CA (1) | CA2410177C (es) |
CY (1) | CY1106947T1 (es) |
CZ (1) | CZ20024098A3 (es) |
DE (1) | DE60129698T2 (es) |
DK (1) | DK1294714T3 (es) |
EC (1) | ECSP024390A (es) |
ES (1) | ES2291323T3 (es) |
HK (1) | HK1051183A1 (es) |
HU (1) | HUP0303081A3 (es) |
IL (2) | IL153308A0 (es) |
MX (1) | MXPA02012447A (es) |
MY (1) | MY130642A (es) |
NO (1) | NO325690B1 (es) |
NZ (1) | NZ523075A (es) |
PE (1) | PE20020235A1 (es) |
PL (1) | PL359822A1 (es) |
PT (1) | PT1294714E (es) |
RU (1) | RU2293735C2 (es) |
SK (1) | SK287026B6 (es) |
TW (1) | TWI302913B (es) |
WO (1) | WO2001096330A2 (es) |
ZA (1) | ZA200210099B (es) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
DK1294714T3 (da) * | 2000-06-15 | 2007-12-03 | Schering Corp | Trombinreceptorantagonister |
US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
HUP0500443A3 (en) | 2001-10-18 | 2009-12-28 | Schering Corp | Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them |
TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
EP1860106B1 (en) * | 2002-04-16 | 2010-01-20 | Schering Corporation | Tricyclic thrombin receptor antagonists |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
ATE536889T1 (de) * | 2003-07-08 | 2011-12-15 | Accumetrics Inc | Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten |
US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7407753B2 (en) * | 2004-05-24 | 2008-08-05 | Yissum Research Development Company Of The Hebrewuniversityofjerusalem | Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis |
EP1751144B1 (en) * | 2004-05-28 | 2008-08-27 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
WO2006023844A2 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
WO2006042017A2 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
EP2075250B1 (en) * | 2004-10-08 | 2015-03-04 | Merck Sharp & Dohme Corp. | Thrombin receptor antagonists |
US20070037831A1 (en) * | 2004-11-18 | 2007-02-15 | Cynthia Cuffie-Jackson | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure |
MX2007008622A (es) * | 2005-01-14 | 2007-09-11 | Schering Corp | Una sintesis exo-selectiva de analogos de himbacina. |
US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
EP2196454B1 (en) | 2005-01-14 | 2014-08-27 | Merck Sharp & Dohme Corp. | Exo-and diastereo-selective syntheses of himbacine analogs |
KR20070116066A (ko) | 2005-03-31 | 2007-12-06 | 쉐링 코포레이션 | 스피로사이클릭 트롬빈 수용체 길항제 |
US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
US7875633B2 (en) | 2005-08-24 | 2011-01-25 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
EP1953165B1 (en) | 2005-11-10 | 2012-02-01 | Msd K.K. | Aza-substituted spiro derivative |
US20070219154A1 (en) * | 2005-12-20 | 2007-09-20 | Suxing Liu | Methods for preventing and/or treating a cell proliferative disorder |
WO2007075964A2 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
WO2007075809A2 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Oxazoloisoquinoline derivatives as thrombin receptor antagonists |
AR060095A1 (es) | 2006-03-29 | 2008-05-21 | Schering Corp | Derivados de himbacina monociclicos y biciclicos utiles como antogonistas de los receptores de trombina |
MX2008013246A (es) | 2006-04-13 | 2008-10-21 | Schering Corp | Antagonistas del receptor de trombina de anillo fusionado. |
AR061664A1 (es) | 2006-06-29 | 2008-09-10 | Schering Corp | Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas. |
US20080026050A1 (en) * | 2006-06-30 | 2008-01-31 | Rajan Gupta | Solid dose formulations of a thrombin receptor antagonist |
TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
CN101595107A (zh) * | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
MX2009003758A (es) * | 2006-10-04 | 2009-04-22 | Schering Corp | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina. |
JP2010505842A (ja) * | 2006-10-04 | 2010-02-25 | シェーリング コーポレイション | トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体 |
WO2008079260A2 (en) * | 2006-12-22 | 2008-07-03 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
AU2008230116A1 (en) * | 2007-03-23 | 2008-10-02 | Schering Corporation | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
CN101675342A (zh) * | 2007-05-03 | 2010-03-17 | 阿库米特里克斯股份有限公司 | 测量凝血酶受体拮抗剂对血小板聚集的抑制的方法 |
CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
WO2009143039A2 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
JP5575137B2 (ja) | 2008-10-22 | 2014-08-20 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体 |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
ES2437100T3 (es) | 2009-06-04 | 2014-01-08 | Merck Sharp & Dohme Corp. | Metabolito activo de un antagonista de los receptores de la trombina |
US20120141586A1 (en) | 2009-06-08 | 2012-06-07 | Rubi Burlage | Thrombin receptor antagonist and clopidogrel fixed dose tablet |
AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
ES2527535T3 (es) | 2010-04-16 | 2015-01-26 | Sanofi | Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1 |
PL2558465T3 (pl) | 2010-04-16 | 2015-05-29 | Sanofi Sa | Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1) |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
JP5728099B2 (ja) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体 |
US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
EP2822557B1 (en) | 2012-03-06 | 2017-08-23 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
WO2015013083A1 (en) | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
WO2015026693A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
EP3035930A4 (en) | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
WO2015026686A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
WO2016058144A1 (en) * | 2014-10-15 | 2016-04-21 | Merck Sharp & Dohme Corp. | Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
WO2022018156A1 (en) | 2020-07-22 | 2022-01-27 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト[2,3−c]フラン誘導体およびその製造方法 |
US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
DK1036072T3 (da) * | 1997-11-25 | 2004-09-06 | Schering Corp | Thrombinreceptorantagonister |
DE19801636A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte bicyclische Lactone |
DK1294714T3 (da) * | 2000-06-15 | 2007-12-03 | Schering Corp | Trombinreceptorantagonister |
-
2001
- 2001-06-13 DK DK01944492T patent/DK1294714T3/da active
- 2001-06-13 CZ CZ20024098A patent/CZ20024098A3/cs unknown
- 2001-06-13 IL IL15330801A patent/IL153308A0/xx unknown
- 2001-06-13 RU RU2003101111/04A patent/RU2293735C2/ru not_active IP Right Cessation
- 2001-06-13 AR ARP010102821A patent/AR028952A1/es active IP Right Grant
- 2001-06-13 ES ES01944492T patent/ES2291323T3/es not_active Expired - Lifetime
- 2001-06-13 EP EP01944492A patent/EP1294714B1/en not_active Expired - Lifetime
- 2001-06-13 AU AU6690001A patent/AU6690001A/xx active Pending
- 2001-06-13 PL PL35982201A patent/PL359822A1/xx unknown
- 2001-06-13 KR KR1020027016982A patent/KR100604742B1/ko not_active IP Right Cessation
- 2001-06-13 NZ NZ523075A patent/NZ523075A/en unknown
- 2001-06-13 MY MYPI20012768 patent/MY130642A/en unknown
- 2001-06-13 CN CNB018111483A patent/CN1203070C/zh not_active Expired - Fee Related
- 2001-06-13 EP EP10185528.6A patent/EP2301930B1/en not_active Expired - Lifetime
- 2001-06-13 PT PT01944492T patent/PT1294714E/pt unknown
- 2001-06-13 CA CA2410177A patent/CA2410177C/en not_active Expired - Fee Related
- 2001-06-13 MX MXPA02012447A patent/MXPA02012447A/es active IP Right Grant
- 2001-06-13 JP JP2002510472A patent/JP4642318B2/ja not_active Expired - Fee Related
- 2001-06-13 SK SK1755-2002A patent/SK287026B6/sk not_active IP Right Cessation
- 2001-06-13 BR BR0111991-5A patent/BR0111991A/pt not_active Application Discontinuation
- 2001-06-13 TW TW090114230A patent/TWI302913B/zh not_active IP Right Cessation
- 2001-06-13 US US09/880,222 patent/US6645987B2/en not_active Expired - Lifetime
- 2001-06-13 DE DE60129698T patent/DE60129698T2/de not_active Expired - Lifetime
- 2001-06-13 WO PCT/US2001/019025 patent/WO2001096330A2/en active IP Right Grant
- 2001-06-13 AT AT01944492T patent/ATE368659T1/de not_active IP Right Cessation
- 2001-06-13 PE PE2001000558A patent/PE20020235A1/es not_active Application Discontinuation
- 2001-06-13 AU AU2001266900A patent/AU2001266900B2/en not_active Ceased
- 2001-06-13 HU HU0303081A patent/HUP0303081A3/hu unknown
-
2002
- 2002-12-06 IL IL153308A patent/IL153308A/en not_active IP Right Cessation
- 2002-12-12 NO NO20025965A patent/NO325690B1/no not_active IP Right Cessation
- 2002-12-12 ZA ZA200210099A patent/ZA200210099B/en unknown
- 2002-12-13 EC EC2002004390A patent/ECSP024390A/es unknown
-
2003
- 2003-04-11 HK HK03102658A patent/HK1051183A1/xx not_active IP Right Cessation
- 2003-06-09 US US10/457,256 patent/US6894065B2/en not_active Expired - Lifetime
-
2006
- 2006-12-06 JP JP2006329955A patent/JP2007056043A/ja not_active Withdrawn
-
2007
- 2007-10-22 CY CY20071101356T patent/CY1106947T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR028952A1 (es) | Antagonistas receptores de trombina | |
RU2330038C2 (ru) | Конденсированные гетероциклические сукцинимидные соединения и их аналоги как модуляторы функций рецептора гормонов ядра | |
DE60021282D1 (de) | Carbamat-derivate als muscarin-rezeptor antonisten | |
EA200200628A1 (ru) | Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a | |
NO20032253D0 (no) | Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer | |
FR2838439B1 (fr) | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
CY1106076T1 (el) | Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια | |
WO2003086303A3 (en) | Farnesoid x-activated receptor agonists | |
UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
UY26750A1 (es) | Derivados de tiofeno útiles como agentes anticancerosos | |
UY26780A1 (es) | Cicloalquil avb3 antagonistas | |
EA200200912A1 (ru) | Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
HRP20050213A2 (en) | 2,4-substituted indoles and their use as 5-ht6 modulators | |
PA8495101A1 (es) | Derivados de 13-metileritromicina | |
DE60324544D1 (de) | Muskarin antagonisten | |
UY26812A1 (es) | Derivados de 1-sulfonil-pirrolidina | |
UY29169A1 (es) | Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
AR027539A1 (es) | Nuevos derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |